Belite Bio, Inc (BLTE) is a publicly traded company in the Healthcare — Biotechnology industry listed on NASDAQ. This overview shows the latest price, key valuation ratios, profitability metrics and financial-health indicators used by fundamental investors.
Belite Bio, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and advancement of novel therapies. The firm's primary therapeutic areas include atrophic age-related macular degeneration and autosomal recessive Stargardt disease. Its flagship drug candidate, LBS-008, is an investigational oral medication administered once daily.
Is Belite Bio, Inc stock overvalued or undervalued in 2026?
As of November 3, 2026, Belite Bio, Inc (BLTE) trades at $152.17 with no positive earnings over the last twelve months, according to Kaplio. No valuation verdict: it has no earnings to calculate a P/E from.
Kaplio overview: Belite Bio, Inc
Market cap $6B · 52 weeks $106 – $194 (21 % below the high) · P/E no earnings · 2027 est. P/E 80.1× · Dividend none · Next earnings November 9, 2026 · expected EPS -$0.79 · Closing price, Nov 3 · accounts published Aug 12.
- Valuation: P/E — (no earnings).
- Balance sheet: Safe zone (solid).
- Earnings: 4 of 8 (uneven).
What would it be worth at its usual multiples?
No valuation verdict: it has no earnings to calculate a P/E from.
What matters in biotech: 2 of 4 pass
- R&D / Market cap 0.0 %, fails.
- Market cap / Cash 10.4×, fails.
- Cash Runway 160 months, passes.
- Total Debt 0.0×, passes.
- Annual cash burn $1.10, info.
Against its peers (reference peers) — Belite Bio, Inc: P/E —; EV/EBITDA —; ROIC -15.3 %; $6.1B. Ligand Pharmaceuticals Incorporated (P/E 140×; EV/EBITDA 93.2×; ROIC 2.3 %; $6.3B), PTC Therapeutics, Inc. (P/E —; EV/EBITDA 29.9×; ROIC 5.7 %; $5.7B), Krystal Biotech, Inc. (P/E 41.4×; EV/EBITDA 34.4×; ROIC 15.8 %; $9.0B).
Profitability
| Return on Equity | -15.65% |
| Return on Invested Capital | -15.28% |
| Return on Assets | -12.93% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Financial Health
| Debt / Equity | 0.00 |
| Current Ratio | 33.56 |
| Piotroski F-Score | 3 |
| Altman Z-Score | 319.70 |
Price Performance
| 1 month | -3.46% |
| 3 months | -4.36% |
| Year-to-date | -3.93% |
| 1 year | +38.34% |
| 3 years | +293.72% |
Related companies: KOD · VRTX · 0QZU.L · REGN · MRNA · 0R2M.L · ARGX · 0QNO.L
Explore sector: Healthcare · Biotechnology
More sections of BLTE: Financials · Valuation · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Companies that pass the Buffett method · Companies that pass the Lynch method · Stocks that pass Graham's defensive investor test today · Investment Academy — learn to analyze stocks